EU CHMP recommends extended indication of Ryzodeg (insulin degludec plus insulin aspart) for diabetes mellitus in adults, adolescents and children from the age of 2 years- Novo Nordisk
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ryzodeg (insulin degludec plus insulin aspart), from Novo Nordisk. The CHMP adopted a change to the existing indication which now reads: treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Comment: As a combination of two distinct insulin analogues, Ryzodeg is the first combination of a basal insulin with a long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins